Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled IBIO123 in Severe COVID-19
NCT05303376Phase 2Completed
- Sponsor
- Immune Biosolutions
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of IBIO123 in coronavirus disease 2019 (COVID-19), sponsored by Immune Biosolutions. Primary endpoints: Safety and tolerability at Day 7 and SARS-CoV-2 viral load and viral clearance at Day 5. Started Feb 2022; status: completed.
02
Drugs
IBIO123
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05303376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303376.